Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Terazaki

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
International Journal of Oncology|October 14, 2014
Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimensTeppei Yamada, Yasuhiro Terazaki, Shinjiro Sakamoto, et al.
Cancer Science|February 11, 2012
Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancerYasuhiro Terazaki, Koichi Yoshiyama, Satoko Matsueda, et al.
Plos One|May 19, 2023
Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201Hiromasa Yamamoto, Junichi Soh, Norihito Okumura, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
International Journal of Oncology|October 14, 2014
Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimensTeppei Yamada, Yasuhiro Terazaki, Shinjiro Sakamoto, et al.
Cancer Science|February 11, 2012
Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancerYasuhiro Terazaki, Koichi Yoshiyama, Satoko Matsueda, et al.
Plos One|May 19, 2023
Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201Hiromasa Yamamoto, Junichi Soh, Norihito Okumura, et al.
Pageof 3